Related references
Note: Only part of the references are listed.Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
Nuruddeen D. Lewis et al.
MOLECULAR CANCER THERAPEUTICS (2021)
A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties
Kevin Dooley et al.
MOLECULAR THERAPY (2021)
Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment
Sarah A. O'Brien et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
Su Chul Jang et al.
COMMUNICATIONS BIOLOGY (2021)
The biology, function, and biomedical applications of exosomes
Raghu Kalluri et al.
SCIENCE (2020)
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy
Martina Molgora et al.
CELL (2020)
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1
Theresa A. Proia et al.
CLINICAL CANCER RESEARCH (2020)
The transcription factor EGR2 is the molecular linchpin connecting STAT6 activation to the late, stable epigenomic program of alternative macrophage polarization
Bence Daniel et al.
GENES & DEVELOPMENT (2020)
Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency
Christina Schindler et al.
PLOS ONE (2019)
Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication
Chin-Yap Loh et al.
FRONTIERS IN ONCOLOGY (2019)
RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment
Xing-Yu Mu et al.
MOLECULAR IMMUNOLOGY (2019)
Macrophages in Colorectal Cancer Liver Metastases
Nina Cortese et al.
CANCERS (2019)
Immunotherapy for hepatocellular carcinoma: Current and future
Michael P. Johnston et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Macrophages and hepatocellular carcinoma
Zhiqiang Tian et al.
CELL AND BIOSCIENCE (2019)
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery
Molly A. Taylor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Macrophages as regulators of tumour immunity and immunotherapy
David G. DeNardo et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer
Karin Binnemars-Postma et al.
FASEB JOURNAL (2018)
The Transcription Factor STAT6 Mediates Direct Repression of Inflammatory Enhancers and Limits Activation of Alternatively Polarized Macrophages
Zsolt Czimmerer et al.
IMMUNITY (2018)
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
Jennifer L. Guerriero
TRENDS IN MOLECULAR MEDICINE (2018)
Targeting Macrophages in Cancer: From Bench to Bedside
Ashleigh R. Poh et al.
FRONTIERS IN ONCOLOGY (2018)
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy
Matthew M. Gubin et al.
CELL (2018)
Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
mTHPC-loaded extracellular vesicles outperform liposomal and free mTHPC formulations by an increased stability, drug delivery efficiency and cytotoxic effect in tridimensional model of tumors
Marie Millard et al.
DRUG DELIVERY (2018)
Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors
Luca Cassetta et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Sushrut Kamerkar et al.
NATURE (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
The transcription factor MafB promotes anti-inflammatory M2 polarization and cholesterol efflux in macrophages
Hwijin Kim
SCIENTIFIC REPORTS (2017)
Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors
Vinit Kumar et al.
CANCER CELL (2017)
IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model
Shuku-ei Ito et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk
Viviana Piccolo et al.
NATURE IMMUNOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Tumor-associated macrophages in cancers
W. Hu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER
Wolf Heusermann et al.
JOURNAL OF CELL BIOLOGY (2016)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Megan M. Kaneda et al.
CANCER DISCOVERY (2016)
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Anna-Maria Georgoudaki et al.
CELL REPORTS (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
Richard S. Geary et al.
CLINICAL PHARMACOKINETICS (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David Hong et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The Emerging Understanding of Myeloid Cells as Partners and Targets in Tumor Rejection
Miranda L. Broz et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy
Felix Klug et al.
CANCER CELL (2013)
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Ryszard Kole et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Transcriptional regulation by STAT6
Shreevrat Goenka et al.
IMMUNOLOGIC RESEARCH (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Alternative activation of tumor-associated macrophages by IL-4 Priming for protumoral functions
Hao-Wei Wang et al.
CELL CYCLE (2010)
Genome-wide Profiling of Interleukin-4 and STAT6 Transcription Factor Regulation of Human Th2 Cell Programming
Laura L. Elo et al.
IMMUNITY (2010)
Alternative Activation of Macrophages: Mechanism and Functions
Siamon Gordon et al.
IMMUNITY (2010)
Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl] amino} pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors
Shinya Nagashima et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression
Fernando O. Martinez et al.
JOURNAL OF IMMUNOLOGY (2006)
Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease
P Sinha et al.
JOURNAL OF IMMUNOLOGY (2005)
The Th2 cell cytokines IL-4 and IL-13 regulate found in inflammatory zone 1/resistin-like molecule α gene expression by a STAT6 and CCAAT/enhancer-binding protein-dependent mechanism
AM Stütz et al.
JOURNAL OF IMMUNOLOGY (2003)
Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma
S Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2000)
Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice
AK Kacha et al.
JOURNAL OF IMMUNOLOGY (2000)